T-cell associated antigen-positive B-cell lymphoma

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• B-cell non-Hodgkin's lymphoma (B-NHL) is a heterogeneous group of lymphoid malignancies.
• Aberrant antigen expression, including T-cell associated antigens (T-Ag), can occur in B-NHL.
• The clinical significance and diagnostic utility of T-Ag coexpression in B-NHL require further investigation.

Purpose of the Study:

• To investigate the frequency and spectrum of T-cell associated antigen (T-Ag) coexpression in B-NHL.
• To evaluate the clinical features associated with T-Ag coexpression in B-NHL.
• To assess the utility of T-Ag detection for minimal residual disease (MRD) monitoring in T-Ag(+) B-NHL.

Main Methods:

• Two-color flow cytometry (FCM) was employed to immunophenotype 128 B-NHL patients.
• Analysis focused on the coexpression of T-cell associated antigens (CD2, CD5, CD7) on lymphoma cells.
• Clinical data, including extranodular involvement and International Prognostic Index (IPI), were correlated with T-Ag expression.

Main Results:

• T-cell associated antigens (T-Ag) were coexpressed in 24.2% of B-NHL patients, with CD5 being the most frequent (18.0%).
• Extranodular involvement and higher IPI scores were more prevalent in T-Ag(+) B-NHL compared to T-Ag(-) B-NHL.
• Two-color FCM detection of T-Ag is potentially useful for MRD monitoring in T-Ag(+) B-NHL.

Conclusions:

• Aberrant T-cell antigen expression is a notable finding in a subset of B-NHL.
• T-Ag coexpression may be associated with specific clinical characteristics and prognostic indicators in B-NHL.
• Flow cytometry for T-Ag detection offers a valuable tool for MRD monitoring in T-Ag(+) B-NHL patients.